enzastaurin + gemcitabine

Phase 2Completed
0 watching 0 views this week Active
52
Hype Score

Development Stage

Pre-clinical
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Pancreatic Neoplasm

Conditions

Pancreatic Neoplasm

Trial Timeline

Dec 1, 2005 → May 1, 2008

About enzastaurin + gemcitabine

enzastaurin + gemcitabine is a phase 2 stage product being developed by Eli Lilly for Pancreatic Neoplasm. The current trial status is completed. This product is registered under clinical trial identifier NCT00267020. Target conditions include Pancreatic Neoplasm.

Hype Score Breakdown

Clinical
17
Activity
12
Company
10
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT00267020Phase 2Completed

Competing Products

20 competing products in Pancreatic Neoplasm

See all competitors